HRV Pharma's CEO examines the implications of cheaper GLP-1 obesity drugs coming to India post-semaglutide patent expiry, highlighting both transformative potential and misuse risks requiring careful regulation.
Our leadership analyzes impact of US 50% tariffs on Indian pharmaceutical exports, highlighting challenges for SMEs and strategic responses including market diversification.
HRV Pharma's CEO Hari Kiran Chereddi analyzes India's pharmaceutical transformation from affordable generics manufacturer to global hub of compliance, innovation, and supply chain excellence.
HRV Pharma's CEO Hari Kiran Chereddi analyzes India's strategic opportunity in GLP-1 drug manufacturing as Semaglutide patents expire in 2026, emphasizing the shift from reverse engineering to innovative design.
HRV Pharma's CEO Hari Kiran Chereddi outlines strategic recalibration approach to US drug pricing policies, emphasizing global diversification and value-based transformation over reactive market responses.
HRV Pharma is redefining pharmaceutical manufacturing through distributed orchestration, compliance-driven models, and technology-first strategies to build resilient, globally connected supply chains for the future.
Analysis of President Trump's Most Favored Nation executive order impact on generic and biosimilar markets, with HRV Pharma's strategic insights on opportunities for Indian pharmaceutical manufacturers
HRV Pharma is reshaping pharmaceutical manufacturing through compliance-first strategies, distributed orchestration, and technology-driven innovation, as featured in Express Pharma’s June 2025 edition.
Comprehensive analysis of key forces driving pharmaceutical industry transformation, from biotech advances and AI-powered drug discovery to emerging markets and virtual pharma models reshaping global healthcare.
Explore how AI, automation, and real-time analytics are transforming generic drug production through smart manufacturing and continuous processes.
Our CEO Hari Kiran Chereddi shares insights in Citeline Medtech Insight on India's role in global supply chains amidst US medical device tariffs.
Discover how Indian pharma can leverage US tariff relief to strengthen partnerships, innovate, and maintain global competitiveness in healthcare affordability.
HRV Pharma's Sreenivas Varma discusses India's API industry transformation, PLI schemes, and the shift towards high-value pharmaceutical manufacturing.
The possibility of increased US tariffs has sparked concerns within the Indian pharmaceutical sector. However, instead of viewing this as a setback, it's time to consider it a catalyst for strategic reinvention and growth.
HRV Pharma's leadership discusses strategic approaches for Indian pharmaceutical companies to navigate potential US tariff challenges while maintaining global competitiveness and healthcare affordability.
The pharmaceutical industry is undergoing a revolution, powered by Artificial Intelligence (AI). As highlighted in a recent article, AI is transforming drug discovery, clinical trials, disease diagnosis, and manufacturing processes.
Hari Kiran Chereddi shares strategic insights on Indian pharma’s US expansion via acquisitions, regulatory agility, and supply chain resilience in a competitive market.
CEO Hari Kiran Chereddi highlights HRV’s virtual manufacturing model, blending AI and blockchain to redefine pharma production and global market access.
HRV Pharma has announced its strategic interest in expanding operations into Sri Lanka, positioning the island nation as a key growth market in the company's South Asian expansion strategy.
HRV’s CEO discusses virtual pharma models and navigating complex global markets in a CPhI Milan interview, emphasizing innovation and regulatory mastery.
CNN Business Arabic highlights HRV Global's resilient supply chain strategies and ambitious Middle East expansion plans, showcasing success in complex markets including Iran, Iraq, and UAE.
HRV Pharma has been honored with two prestigious leadership awards, recognizing the company as a leading pharmaceutical enterprise in both India and the Middle East markets